^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | cisplatin/vinblastine/SHAO-FA (INT230-6) (DNA synthesis inhibitor, Microtubule inhibitor, DNA cross linking agent, Apoptosis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 in early stage breast cancer: The INVINCIBLE trial.
Published date:
05/25/2023
Excerpt:
Women with newly diagnosed and awaiting surgery for early-stage intermediate or high-grade ER+ T1-T2 invasive breast cancers were recruited to the trial….Significant tumor necrosis was observed in the majority of subjects injected with INT230-6….This is the first study evaluating the potential biologic effects of intratumoral cytotoxicity with INT230-6 and its role as a potential immune priming therapy in traditional immune quiescent ER+ breast cancers.
DOI:
10.1200/JCO.2023.41.16_suppl.573
Trial ID:
